Company Tibet Duo Rui Pharmaceutical Co., Ltd.

301075

CNE100004RW5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 30/07/2026			5-day change	1st Jan Change
45.01 ^CNY	-7.25%		-14.56%	-24.57%

04-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Business description: Tibet Duo Rui Pharmaceutical Co., Ltd.

Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Number of employees: 461

Sales by Activity: Tibet Duo Rui Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Preparations	-	298M	235M	187M	55.36M
Active Pharmaceutical Ingredient (api)	-	-	-	10.32M	49.74M
Intermediate	-	103M	99.61M	38M	38.96M
Others	64.26M	-	-	5.51M	10.11M
Sodium Acetate Ringer's Injection	465M	-	-	-	-

See all business segments

Geographical breakdown of sales: Tibet Duo Rui Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
China	530M	401M	334M	241M	154M

See all geographic segments

Executive Committee: Tibet Duo Rui Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	30/11/2018
Chao Li DFI	Director of Finance/CFO	47	30/04/2017
Fen Jin DFI	Director of Finance/CFO	46	30/11/2017
Ying Liu IRC	Investor Relations Contact	39	-
Bo Ao PRN	Corporate Officer/Principal	40	22/03/2022

See TIBET DUO RUI PHARMACEUTICAL CO., LTD. governance

Composition of the Board of Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	30/11/2017
Shao Zhong Zhang BRD	Director/Board Member	70	20/02/2020
Qin Deng BRD	Director/Board Member	58	20/02/2020
Ying Fei Liu BRD	Director/Board Member	48	20/02/2020
Fei Qi BRD	Director/Board Member	49	20/02/2020
Fen Jin BRD	Director/Board Member	46	14/04/2022
Yun Guo Wang BRD	Director/Board Member	54	14/04/2022

Composition of the Board of Directors

Shareholders: Tibet Duo Rui Pharmaceutical Co., Ltd.

Name	Stocks	%	Valuation
China Asset Management Co., Ltd. 0.0394 %	10,800	0.0394 %	90 740 ¥
Orient Fund Management Co., Ltd. 0.0263 %	7,200	0.0263 %	60 493 ¥
CCB Principal Asset Management Co., Ltd. 0.002188 %	600	0.002188 %	5 041 ¥

List of TIBET DUO RUI PHARMACEUTICAL CO., LTD. shareholders

Company details: Tibet Duo Rui Pharmaceutical Co., Ltd.

Tibet Duo Rui Pharmaceutical Co., Ltd.

3/F, Building 1, Biomedical Park

854000, Changdu

http://www.duoruiyy.com

address Tibet Duo Rui Pharmaceutical Co., Ltd.(301075)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-7.25%	-14.56%	+26.43%	+80.33%	566M
ELI LILLY AND COMPANY	-3.98%	-1.67%	+53.42%	+156.54%	1,079B
JOHNSON & JOHNSON	-3.63%	-1.13%	+53.25%	+53.01%	640B
ABBVIE INC.	-1.94%	+0.51%	+36.41%	+72.64%	465B
ROCHE HOLDING AG	-2.29%	+1.12%	+36.13%	+30.60%	353B
NOVARTIS AG	-2.28%	-0.69%	+33.42%	+39.21%	301B
ASTRAZENECA PLC	-3.15%	+0.25%	+10.63%	+13.71%	271B
NOVO NORDISK A/S	-2.12%	+3.31%	+1.82%	-39.41%	228B
AMGEN INC.	-0.79%	+3.39%	+27.45%	+64.04%	209B
GILEAD SCIENCES, INC.	-2.15%	-0.73%	+13.19%	+70.61%	165B
Average	-2.96%	+3.31%	+29.22%	+54.13%	371.02B
Weighted average by Cap.	-2.93%	+4.86%	+38.45%	+75.20%